Work

PS2-05-24: Histopathological Grade as a Prognostic Marker in de novo Metastatic HER2-Positive Breast Cancer Treated with First-Line Docetaxel, Trastuzumab, and Pertuzumab

Year: 2026

Type: article

Study design: Observational Study

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps2-05-24

Authors: M. Kubeczko, M. Mianowska-Malec, A. Polakiewicz-Gilowska, K. Swiderska, A. Lesniak, B. Lanoszka, B. Grandys, K. Chomik, N. Lisovska, B. Pycinski, E. Stobiecka, J. Simek, E. Chmielik, A. Prat, M. Jarzab

Institutions: The Maria Sklodowska-Curie National Research Institute of Oncology, Silesian University of Technology, Hospital Clínic de Barcelona, Solti, Universitat de Barcelona

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129689449

FWCI:

Cites:

Cited by:

Related to: